Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader
in the development and sale of broadly enabling, pressure-based technology and
products to the worldwide life sciences and other industries, on Tuesday
announced that it will host a teleconference to discuss its second quarter 2019
financial results and to provide a business update. The teleconference is
scheduled for 4:30 PM ET on Thursday, August 15, 2019, and will include a
company presentation followed by a question and answer period. Interested
parties may listen to the teleconference live by dialing (844) 602-0380 (North
America); (862) 298-0970 (International) and entering the following verbal
passcode for the operator: PBI Second Quarter 2019 Financial Call and Business
Update. For those unable to participate in the live teleconference, a replay
will be available beginning Friday, August 16, 2019, and will be accessible via
telephone and the company’s website for 30 days. Interested parties may listen
to the replay by dialing (877) 481-4010 (North America); (919) 882-2331
(International) and entering replay passcode: 53312.
To view the full press release, visit http://ibn.fm/7IZxr
About Pressure BioSciences Inc.
Pressure BioSciences (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life-sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a
patented-enabling technology platform that uses alternating cycles of
hydrostatic pressure between ambient and ultra-high levels to safely and
reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule
extraction). PBIO’s primary focus is in the development of PCT-based products
for biomarker and target discovery, drug design and development,
biotherapeutics characterization and quality control, soil and plant biology,
forensics and counter-bioterror applications. Additionally, major new market
opportunities have emerged in the use of the company’s pressure-based
technologies in the following areas: (1) the use of its recently acquired
PreEMT technology from BaroFold Inc. to allow entry into the biologics-contract,
research-services sector, and (2) the use of its recently patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i)
create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and
water) and (ii) prepare higher-quality, homogenized, extended shelf-life or
room-temperature stable, low-acid liquid foods that cannot be effectively
preserved using existing nonthermal technologies. For more information, visit
the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
